Corporation
GlaxoSmithKline Inc.
- Meetings this Parliament
- 48
- With MPs
- 11
- Since Nov 2021
- 166
- Active registrations
- 1
Most recent reported meeting: Sep 15, 2026.
Lobbying by GlaxoSmithKline Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since Sep 15, 2026
Filed by Tina Graves, President and General Manager, GSK Canada
Lobbyists
- Alain Couture · External Affairs Manager
- Alison Pozzobon · Vice President Communications, Government Affairs and Market Access
- Bryan Tennant · Scientific Director
- Emily Beduz · Manager, Federal Affairs
- Gilda Volpentesta · VP of Regulatory
- Ian Robertson · Senior Manager, Government Affairs and Public Health
- Kevin Sauve · National Public Health Manager
- Lisa Lovlin · Senior Manager, Government Affairs and Public Health
- Luke Miels · Global CEO
- Michelle Horn · VP & Country Medical Director
- Ryan Lock · Manager, National Policy - Federal Affairs
- Shawn White · External Affairs Manager
- Stephen Burke · National Policy Manager - Oncology
- Steven A Roberts · Director, Scientific Collaborations
- Tina Graves · President and General Manager, GSK Canada
Institutions they may lobby: Canadian Heritage (PCH), Correctional Service of Canada (CSC), Employment and Social Development Canada (ESDC), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Immigration, Refugees and Citizenship Canada (IRCC), Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Justice Canada (JC), Pacific Economic Development Canada (PacifiCan), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Senate of Canada, Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)
What they're lobbying on (26)Hide details
- Engagement with the Government regarding the Life Science Fund seeking partnership and funding to support completion of Phase I and Phase II clinical research program associated to AMR (antimicrobial resistance)
- Antimicrobial Resistance (AMR) - Seek funding and support for pilot projects making anti-infective medications available to equity seeking populations, helping to combat AMR. Also discuss any applicable conditions regarding this funding.
- Programs and policy to support Canadian biomanufacturing and access to medicines and vaccines for Canadians.
- National Immunization Strategy and policies and programs that impact public access to vaccines and disease prevention in Canada.
- Patented Medicines Review Board (PMPRB), certified under the Patent Act and whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development.
- Engagement with federal officials regarding the Biomanufacturing & Life Sciences Strategy and policies and programming related to biomanufacturing in Canada
- Access to medicines - government policies, processes, legislation, and/or regulation with potential impact on access to medicines in Canada.
- Trade-related matters, including policies and tariffs impacting medicines and vaccines.
- Policies and programs related to the health of new immigrants to Canada.
- Policies, programs, and funding related to Canada's Sexually Transmitted and Blood-Borne Infections (STBBI) Action Plan 2024-2030.
- Engagement with federal officials regarding Health Emergency Readiness Canada.
- The National Pharmaceutical Strategy (NPS) as agreed by First Ministers in 2004. Advocacy for ways to increase access to medicines and vaccines for Canadian patients.
- The Common Drug Review (CDR) process for reviewing new drugs and providing listing recommendations to publicly funded drug benefit plans in Canada. Ensuring the access needs of Canadian patients are met by advocating on activities undertaken in the context of the CDR.
- Science and Technology (S&T) Strategy: Mobilizing Science and Technology to Canada's Advantage. Advocacy for measures which will allow for commercialization in health care to occur and for Canada to remain competitive internationally on Intellectual Property and other fronts.
- Public Services and Procurement Canada (PSPC) Integrity Framework - Clarifying the process for procurement of vaccines and possibly pharmaceuticals under the evolving procurement framework.
- Patented Medicines (Notice of Compliance) Regulations which seek to balance the protection of Intellectual Property (IP) and patents with cost containment. Advocacy to ensure that IP rights are respected and internationally competitive in order to promote Research and Development.
- Legislation, regulations, policies and programs concerning the federal government's response to COVID-19, including pandemic preparedness, pharmaceutical and vaccine supply-chain management, and general administration of justice.
- Food and Drugs Act and the bill formerly known as Bill C-51: An Act to amend the Food and Drugs Act and to make consequential amendments to other Acts. Specifically, with respect to the renewal of the drug approval process. Advocacy to ensure that Canada's review and approval process is timely, safe, effective, competitive and consistent with other jurisdictions.
- FedDev Ontario Advanced Manufacturing Fund - advancing manufacturing of innovative pharmaceutical products in southern Ontario
- Engage with government to strengthen the Priority Review for Drug Submissions process.
- Engage the Government regarding the need for clear and efficient procurement processes for COVID-19 medical countermeasures, including COVID-19 therapeutics, to ensure access for Canadians.
- Engagement with the Government regarding the Strategic Innovation Fund
- Drug Re-importation - Raise awareness regarding the potential risks to drug and vaccine supply for Canadian patients arising from new U.S. state-level re-importation legislation.
- Canada’s Access to Medicines Regime (CAMR), certified under the Patent Act, which allows developing countries to access drugs at a lower cost, with regard to ensuring that Intellectual Property rights and anti-diversion mechanisms continue to be respected.
- Canada-Europe Comprehensive Economic and Trade Agreement - Intellectual Property Provisions
- Canada-European Union Comprehensive Economic Trade Agreement with respect to strengthening Intellectual Property Protection provisions under the Patent Act and related regulations.
Registration 966444-5088-90. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by Sridhar Venkatesh (145), Zach Gana (10), Faris El-Refaie (8), Tina Graves (3).
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Eric Bourbonnais · Director, Investment Opportunities, Innovation, Science and Economic Development Canada (ISED)
- Jocelyn Milburn · Director, Office of Life Sciences and Biomanufacturing Readiness, Innovation, Science and Economic Development Canada (ISED)
- Celine Menard · Director General, Innovation, Science and Economic Development Canada (ISED)
Economic DevelopmentHealth
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
Economic DevelopmentHealth
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Jean-Yves Duclos · Minister of Health, Health Canada (HC)
- Jamie Kippen · Chief of Staff, Health Canada (HC)
- Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
Economic DevelopmentGovernment ProcurementHealth
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
Economic Development
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Andy Fillmore · Member of Parliament, House of Commons
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
- Darryl Patterson · Director General, Innovation, Science and Economic Development Canada (ISED)
Economic DevelopmentHealth
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Yash Nanda · Policy Advisor, Finance Canada (FIN)
Health
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
Economic DevelopmentHealth
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Bianca Hossain · Senior Special Assistant, Innovation, Science and Economic Development Canada (ISED)
Economic DevelopmentHealth
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
- Jed Graham · Policy advisor, Health Canada (HC)
Health
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Ed Morgan · Director General, Health Canada (HC)
Health
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Jo Voisin · Assistant Deputy Minister, Health Canada (HC)
Health
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
Economic Development
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Patrick Vaughan · Special Assistant Communications and Stakeholder Relations Manager, Employment and Social Development Canada (ESDC)
Health
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Bianca Hossain · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Economic Development
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Yash Nanda · Policy Advisor, Finance Canada (FIN)
BudgetHealth
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
Economic Development
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Jean-Pierre Mizero · Manager, Integration, Outreach & Partnerships, Innovation, Science and Economic Development Canada (ISED)
- Alison McConnell · Deputy Director, Innovation Projects Directorate, Innovation, Science and Economic Development Canada (ISED)
- Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
Economic Development
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Eric Dagenais · Senior Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
- Stephen Lucas · Deputy Minister, Health Canada (HC)
- Nancy Hamzawi · Assistant Deputy Minister, Health Canada (HC)
Health
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
Economic Development
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
Government ProcurementHealth
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
Economic DevelopmentResearch and Development
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Bianca Hossain · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
Economic Development
-
Reported by Sridhar Venkatesh · In-house (corporation)
- Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
- Jean-Sebastien Bock · Director of Policy, Health Canada (HC)
Government ProcurementHealth
-
Reported by Zach Gana · In-house (corporation)
- Zachary Nixon · Senior Advisor, Economic Development and Official Languages
- Camille Benoit-Blouin · Special Assistant, Economic Development and Official Languages
Economic DevelopmentHealth
-
Reported by Zach Gana · In-house (corporation)
- Ashley Wright · Chief of Staff to the Minister, Pacific Economic Development Canada (PacifiCan)
- Jessica La Forge · Policy Advisor, Pacific Economic Development Canada (PacifiCan)
- Neor Tiku · Student, Pacific Economic Development Canada (PacifiCan)
Economic DevelopmentHealthResearch and Development
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.